results

Nagarro releases Q3 2025 results with 9.4% YoY revenue growth in constant currency and 27.2% YoY increase in Adjusted EBITDA; announces share redemption and buyback

MUNICH, Nov. 14, 2025 /PRNewswire/ -- Nagarro, a global digital engineering leader, today presented its unaudited financial numbers for Q3…

4 weeks ago

Sinopec’s Fully Biodegradable PBST Material Tackles Residual Mulch Film Challenge in Xinjiang’s Cotton Fields

WUSU, China, Nov. 14, 2025 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") reported successful results from a pilot of…

1 month ago

Avicanna Reports Q3 2025

November 14, 2025 17:30 ET  | Source: Avicanna Inc. TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or…

1 month ago

Range Impact Reports 3Q 2025 Financial Results

Cleveland, Ohio, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public…

1 month ago

ADNOC Gas Delivers Best-Ever Q3 Results, Demonstrating Resilience and Growth in a Dynamic Market

Record Q3 net income of $1.34 billion, up 8% year-on-year Year-to-date net income of $3.99 billion, up 10% on 2024…

1 month ago

Akums Reports Q2 FY26 Results; Strengthens International Presence

Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second…

1 month ago

Varvee Global Limited (VGL) Posts Strong Operational Profit & EBDITA for Q2FY26: +80% Revenue Growth, 49.8% EBITDA Margin; PAT +23.5% YoY; H1 PAT +15.7% and Attaining Near-Zero Debt

AHMEDABAD, India, Nov. 13, 2025 /PRNewswire/ -- VGL Limited ("VGL" or the "Company") today reported results for the quarter (Q2…

1 month ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…

1 month ago

Hexaware Delivers Q3CY25 Revenue of USD 394.8 Mn, Up 5.5% YoY

Q3CY25 EBITDA Expansion of 154 bps YoY Q3CY25 EPS at INR 6.09, Increase of 22.3% YoY MUMBAI, India and ISELIN,…

1 month ago

Senores Pharma Reports Strong Q2 & H1 FY26 Performance, Sustains Growth Momentum Across Businesses

AHMEDABAD, India, Nov. 7, 2025 /PRNewswire/ -- Senores Pharmaceuticals Limited continued its strong growth trajectory in the second quarter of FY26,…

1 month ago